Docoh
Loading...

TAK Takeda Pharmaceutical

News

From Benzinga Pro
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
28 Nov 21
Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week.
Brand Institute Confirms Earlier Report FDA Approves Takeda's Livtencity
24 Nov 21
News, FDA
Brand Institute is proud to announce its successful partnership with Takeda Pharmaceuticals Company Limited in naming the first treatment approved by the US Food & Drug Administration (FDA) for adults and
Takeda Pharmaceutical Granted Approval For Livtencity
24 Nov 21
News, FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215596
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
24 Nov 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection
24 Nov 21
Biotech, News, Health Care, FDA, General
The
Takeda's LIVTENCITYTM Approved By U.S. FDA As First And Only Treatment For People Ages 12 And Older With Post-Transplant Cytomegalovirus, Refractory To Conventional Antiviral Therapies
23 Nov 21
News, FDA
- In the Phase 3 SOLSTICE study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R) CMV infection/disease achieved confirmed CMV DNA level 56%; n=131/235), compared
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
23 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
21 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, Top Stories, General
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Denali Therapeutics Announces Strategic Partner Takeda Exercises Option To Co-Develop And Co-Commercialize DNL593
17 Nov 21
News, Contracts, FDA
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced
Takeda Pharmaceutical Says Canadian Blood Services Awards Takeda Canada 3-Year Tender For Hemophilia Treatment ADYNOVATE
17 Nov 21
News, Contracts
Takeda Canada is pleased to announce that Canadian Blood Services (CBS) has awarded a three-year tender for ADYNOVATE®i [Antihemophilic Factor (Recombinant) PEGgylated] as part of its request for proposal for recombinant Factor VIII Standard Half-Life (SHL) process as part of its formulary product mix.
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Nov. 15, 2021: Z, LMT, GOOG, NET, U, CLLS, CDXS, TAK, VEEV, REGN, INTU, OPEN
16 Nov 21
Hedge Funds, Trading Ideas, General
Zillow Group (Z) Lockheed Martin (LMT) Alphabet (GOOG) Cloudflare (NET) Unity Software (U) Cellectis (CLLS) Codexis (CDXS) Takeda Pharmaceutical Co (TAK) Veeva Systems (VEEV) Regeneron Pharmaceuticals
Takeda, Shattuck Labs Terminate Immuno-Oncology Pact
9 Nov 21
Biotech, Earnings, News, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General
Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154.
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
2 Nov 21
Biotech, News, Penny Stocks, Health Care, Previews, Small Cap, FDA, Top Stories, Trading Ideas, General
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Nov. 1, 2021: LMT, U, PYPL, TAK, CSTL, IOVA, TXG, NSTG, VEEV, PLTR, PINS, NVDA
2 Nov 21
Hedge Funds, Trading Ideas, General
Lockheed Martin (LMT) - 10,400 Unity Software (U) - 90,958 PayPal Holdings (PYPL) - 1,855 Takeda Pharmaceutical (TAK) - 101,857 Castle Biosciences (CSTL)
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Oct. 29, 2021: PTON, SLGCW, NSTG, TAK, IOVA, VEEV
1 Nov 21
Hedge Funds, Trading Ideas, General
Peloton Interactive (PTON) - 488,016 SomaLogic (SLGCW) - 548,744 Nanostring Technologies (NSTG) - 68,891 Takeda Pharmaceuticals (TAK) - 399,588 Iovance Biotherapeutics
Takeda's 1H Sales Increase 13%, Reaffirms FY21 Outlook, Announces Share Buyback
28 Oct 21
Biotech, Earnings, News, Guidance, Health Care, Buybacks, General
Earnings Scheduled For October 28, 2021
28 Oct 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout
27 Oct 21
Biotech, M&A, News, Health Care, General
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
19 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours:
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
19 Oct 21
Biotech, News, Penny Stocks, Health Care, Contracts, Movers, Trading Ideas, General

Press releases

From Benzinga Pro
Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
23 Nov 21
Press Releases
- In the Phase 3 SOLSTICE study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R) CMV infection/disease achieved confirmed CMV DNA level <LLOQ at Week 8 with LIVTENCITY
Canadian Blood Services Awards Takeda Canada Three-Year Tender for Hemophilia treatment ADYNOVATE®
17 Nov 21
Press Releases
TORONTO, Nov. 17, 2021 /CNW/ - Takeda Canada is pleased to announce that Canadian Blood Services (CBS) has awarded a three-year tender for ADYNOVATE®i [Antihemophilic Factor (Recombinant) PEGgylated] as part of its
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease
4 Nov 21
Press Releases
− New Recommendations Developed in Partnership with Rare Disease Leaders and Experts Aim to Improve the Standard of Care for Rare Disease − New Morning Consult Survey Highlights Wide Gaps in Voters' Knowledge of Rare
Takeda Applied for Selection of "Prime Market", Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
1 Nov 21
Press Releases
Takeda applied for selection to the "Prime Market" of the TSE Corporate Governance Report based on the revised Corporate Governance Code also filed with TSE Published updated corporate governance related
Takeda Announces Acquisition of Own Shares
28 Oct 21
Press Releases
(Pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan) Takeda Pharmaceutical Company Limited ((
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
28 Oct 21
Press Releases
Delivered H1 Year-Over-Year Growth in Reported Revenue of +12.8% and Underlying Revenue of +6.8% 14 Global Brands Represent 42% of Total Core Revenue with +11.4% Underlying Growth in H1; Further Acceleration Expected
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
27 Oct 21
Press Releases
− Acquisition expands Takeda's immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging γδT cells for the potential treatment of solid tumors and hematological malignancies − As result
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
13 Oct 21
Press Releases
First MA center will open in Worcester to support an urgent need for plasma donations used to develop therapies to treat a range of rare and chronic complex conditions BioLife Plasma Services, part of the global
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
7 Oct 21
Press Releases
− If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population − CMV is one of the most common infections experienced by transplant recipients, with an
Takeda Provides Update on TAK-994 Clinical Program
5 Oct 21
Press Releases
Takeda Pharmaceutical Company Limited ((
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
30 Sep 21
Press Releases
− JR-141 is a potentially transformative therapy designed to deliver proteins to the brain and peripheral tissues to treat neuronopathic features along with somatic symptoms of Hunter syndrome via intravenous
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
22 Sep 21
Press Releases
- Global employees based across 80 countries and regions voted to support new partnerships with IntraHealth International, Jhpiego, Pathfinder International and the World Food Programme - New partnerships bring total
Takeda's EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
15 Sep 21
Press Releases
− Approval based on Phase 1/2 trial results, which demonstrated clinically meaningful responses with a median duration of response (DoR) of approximately 1.5 years − Next-generation sequencing (NGS) companion